Category Archives: Uncategorized

20 Jul

Promega Breaks Ground on $190M R&D Building: Slideshow

View the Slideshow Things have been booming at Promega-literally. The Fitchburg, WI-based life science supplies business on Wednesday held a

20 Jul

European Data Infrastructure

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-INFRAEDI-2018-2020Pillar: Excellent ScienceOpening Date: Deadline: Thu, 22 Mar 2018 17:00:00 (Brussels local time)Modification Date: Fri, 20 Jul

20 Jul

PTC Dives Into Gene Therapy with $50M Agilis Biotherapeutics Deal

PTC Therapeutics is looking to gene therapy in a bid to broaden its pipeline, scooping up privately held Agilis Biotherapeutics

19 Jul

European Innovation Council – Top-class innovative projects get €113 million from the EIC SME Instrument

[Source: Research & Innovation] A total of 65 small and medium-sized enterprises (SMEs) from 16 countries have been selected for

19 Jul

#BIOWC18 | Day 3 Wrap-Up

The last day of the 2018 BIO World Congress on Industrial Biotechnology wrapped up Thursday, July 19, with a half-day

19 Jul

San Antonio Sticks to Growth Playbook, Despite Turndowns by Startups

San Antonio-There’s plenty of scrutiny of whether it’s worthwhile for governments to offer incentive packages that aim to attract businesses

18 Jul

Juno’s Fontenot Joins Immusoft as Chief Scientific Officer

Jason Fontenot has been appointed chief scientific officer of Seattle cell therapy developer Immusoft. Fontenot most recently worked at Seattle

18 Jul

MSCA 2018 – Marie Sklodowska-Curie Actions Annual Conference – 1-2 October 2018, Vienna, Austria

[Source: Research & Innovation] The Austrian Federal Ministry of Education, Science and Research will host a Marie Skłodowska-Curie Actions Conference

18 Jul

#BIOWC18 | Day 2 Wrap-Up

At the start of the second day of programming at the 2018 BIO World Congress on Industrial Biotechnology, attendees took

18 Jul

Drug Developer Kiromic Decides Against Move to San Antonio for Cash

San Antonio-The board of directors for Houston-based immunotherapy biotech Kiromic has decided against taking a $200,000 investment from San Antonio-based